97189 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
Glucagon-like peptide 1 receptor agonists and uses thereof
#302Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
#303Methods For Treating Rare Genetic Disorders Using Glucagon Receptor Antagonistic Antibodies
#304Method for treating pathological angiogenesis by administering an antibody that inhibits APLNR
#305Therapeutic and diagnostic methods for autism spectrum disorders and other conditions
#306Peptides and combination of peptides for use in immunotherapy against various cancers
#307Methods Of Treating Type 2 Diabetes Mellitus Using Glucagon Receptor Antagonistic Antibodies
#308Multispecific antigen-binding molecules and uses thereof
#309Lymphocyte cell lines and uses thereof
#310Modulators
#311Human PAC1 antibodies
#312Peptides and combination of peptides for use in immunotherapy against various cancers
#313Peptides and combination of peptides for use in immunotherapy against various cancers
#314Anti-human ADRB3 monoclonal antibody and application thereof in disease diagnosis and treatment
#315Antibody specifically binding to GLP-1R and fusion protein thereof with GLP-1
#316METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMAS
#317TARGETING OF CYTOKINE ANTAGONISTS
#318Targeting of human interferon antagonists
#319Targeted and mutated human-interferon fusion proteins
#320Estrogen receptor mutations and uses thereof
#321Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses
#322Method of treating or ameliorating metabolic disorders using GLP-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (GIPR)
#323METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATORY DISEASES
#324Targeted modified TNF family members
#325Personalized medicine therapeutic MiniCircle
#326Antigen-binding proteins that activate the leptin receptor
#327Antigen-binding proteins that activate the leptin receptor
#328Antibodies which bind human glucagon receptor
#329Medical Use
#330IGF2BP3 functional alterations and overexpression as a marker for cancer diagnosis and therapeutic response to IGF1R inhibitors
#331Methods for treating heart failure using glucagon receptor antagonistic antibodies
#332Antibody Fragments Against the Insulin Receptor and Uses Thereof to Treat Hypoglycemia
#333Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
#334METHODS AND COMPOSITIONS FOR INCREASING IDURONATE 2-SULFATASE ACTIVITY IN THE CNS
#335ANTIBODIES WHICH BIND TYPE I CANNABINOID RECEPTOR/ANGIOTENSIS II RECEPTOR HETEROMERS
#336Chimeric antigen receptors with integrated controllable functions
#337TARGETED MODIFIED IL-1 FAMILY MEMBERS
#338Methods of treating PRLR positive breast cancer
#339Use of chimeric antigen receptor modified cells to treat cancer
#340Targeted modified TNF family members
#341HUMAN CGRP RECEPTOR BINDING PROTEINS
#342Antigen-binding proteins that antagonize leptin receptor
#343Generating targeted sequence diversity in fusion proteins
#344Heterodimeric antibodies that bind somatostatin receptor 2
#345Car t-cell therapy directed to LHR for the treatment of solid tumors
#346CHIMERIC RABBIT/HUMAN ROR1 ANTIBODIES
#347Antagonist antibodies to human prolactin receptor (PRLR)
#348Human PAC1 antibodies
#349Method of Modulating the Concentration of Proteins in Cerebrospinal Fluid
#350Mechanically interlocking complexes
#351Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor antagonistic antibodies
#352Targeting of human interferon antagonists
#353Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrotic diseases
#354Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
#355Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof
#356Targeted human-interferon fusion proteins
#357Stable pharmaceutical solution formulation of GLP-1R antibody fusion protein
#358Classifying hormone receptor status of malignant tumorous tissue from breast thermographic images
#359Blockers of the growth hormone receptor in disease prevention and treatment
#360COMBINATION THERAPIES
#361METHODS OF CONSTRUCTING AMINO TERMINAL IMMUNOGLOBULIN FUSION PROTEINS AND COMPOSITIONS THEREOF
#362Methods of increasing sarcolemmal utrophin
#363Methods and Pharmaceutical Compositions Using Orexins (OXA, OXB) for the Treatment of Prostate Cancers
#364Diagnostic of Obliterative Arteriopathies
#365Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof
#366Anti-PACAP antibodies and uses thereof
#367Humanized anti-PACAP antibodies and uses thereof
#368Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
#369Methods for detecting 1,25-dihydroxyvitamin D and related antibodies
#370Methods, agents and compositions for treatment of inflammatory conditions
#371Human PAC1 antibodies
#372Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
#373Method for minimising progression of cancer in companion animals
#374Methods for improving cardiac function by administering an antibody that activates APLNR
#375Peptides and combination of peptides for use in immunotherapy against various cancers
#376Peptides and combination of peptides for use in immunotherapy against various cancers
#377Peptides and combination of peptides for use in immunotherapy against various cancers
#378Peptides and combination of peptides for use in immunotherapy against various cancers
#379Peptides and combination of peptides for use in immunotherapy against various cancers
#380Peptides and combination of peptides for use in immunotherapy against various cancers
#381METHODS AND COMPOSITIONS FOR EVALUATING BREAST CANCER PATIENTS
#382Peptides and combination of peptides for use in immunotherapy against various cancers
#383Modified serum-free cell culture medium
#384Human antibodies to the glucagon receptor and methods of use thereof for lowering blood glucose or ketone levels
#385Methods and compositions for increasing α-L-iduronidase activity in the CNS
#386Humanized antibodies that bind LGR5
#387Use of negative functional modulators of erythropoietin for therapy
#388Antagonists for abdominal vasopressin V2 receptor and uses thereof
#389Pharmaceutical compositions comprising an antibody which binds the human anti-Müllerian hormone receptor type II
#390Antigen-binding proteins that activate the leptin receptor
#391Method and system for preventing migraine headaches, cluster headaches and dizziness
#392Targeted human-interferon fusion proteins
#393COMPOSITIONS AND METHODS FOR BLOOD-BRAIN BARRIER DELIVERY OF IGG-DECOY RECEPTOR FUSION PROTEINS
#394METHODS, COMPOSITIONS AND KITS FOR CELL SPECIFIC MODULATION OF TARGET ANTIGENS
#395APLNR modulators and uses thereof
#396Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies
#397Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
#398Antibodies, antibody drug conjugates and methods of use
#399Prolactin receptor binding proteins and uses thereof
#400ANTI-PROLACTIN RECEPTOR ANTIBODY FORMULATIONS
#401Multispecific antigen-binding molecules and uses thereof
#402Methods of treating hedgehog-related diseases with an anti-LGR5 antibody
#403Methods and compositions for treating solid tumors and enhancing tumor vaccines
#404Antibody specifically binding to GLP-1 R and fusion protein thereof with GLP-1
#405Methods and monitoring of treatment with a WNT pathway inhibitor
#406METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMAS
#407Therapeutic and diagnostic methods for autism spectrum disorders and other conditions
#408Neutralizing prolactin receptor antibody Mat3 and its therapeutic use
#409Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
#410Methods for treating or preventing migraine headache
#411ANTI-GLUCAGON RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF
#412G-PROTEIN COUPLED RECEPTOR AGONISTS AND METHODS
#413Marker of cell death
#414METHOD OF TREATING STRESS HYPERGLYCEMIA WITH HUMAN ANTIBODIES TO THE GLUCAGON RECEPTOR
#415METHOD OF INCREASING THE EFFECT OF AN ACTIVATED-POTENTIATED FORM OF AN ANTIBODY
#416Methods of treating breast cancer by administering anti-human prolactin receptor (PRLR) antibodies
#417Human PAC1 antibodies
#418Methods and compositions for generation of binding agents against cell surface antigens
#419METHOD OF INCREASING THE EFFECT OF AN ACTIVATED-POTENTIATED FORM OF AN ANTIBODY
#420Method Of Administration To A Patient Suffering From Disturbances In Vascular Tone
#421Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
#422Antibodies which bind type I cannabinoid receptor/angiotensin II receptor heteromers and methods of use
#423Combinatorial antibody libraries and uses thereof
#424Antibody locker for the inactivation of protein drug
#425Pharmaceutical compositions containing sc(Fv)2
#426ANTIBODIES FOR GUANYLYL CYCLASE RECEPTORS
#427Method for treating tumors that possess the CCK-C receptor with the 3B9.1 monoclonal antibody
#428METHOD OF TREATING DIABETES, AND DISEASES ASSOCIATED WITH IMPAIRED GLUCOSE TOLERANCE
#429Targeting of human interferon antagonists
#430Targeted modified TNF family members
#431Targeted modified IL-1 family members
#432Compositions and methods related to structures that cross the blood brain barrier
#433Estrogen receptor mutations and uses thereof
#434Anti-DEspR inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
#435Antibody against human prostaglandin E2 receptor EP4
#436MOLECULAR TARGETS AND COMPOUNDS, AND METHODS TO IDENTIFY THE SAME, USEFUL IN THE TREATMENT OF FIBROTIC DISEASES
#437Antibodies and methods for treating estrogen receptor-associated diseases
#438Human PAC1 antibodies
#439BLOOD-BRAIN-BARRIER DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
#440VETERINARY COMPOSITION AND METHOD OF IMPROVING LIVABILITY OF ANIMALS, PROMOTING LIVE WEIGHT GAIN IN MAMMALS AND BIRDS, ENHANCING THE EFFECTIVENESS OF IMMUNIZATION, AND PREVENTING AND/OR TREATING INFECTIOUS DISEASES
#441Modulators
#442ANTI-PROLACTIN RECEPTOR ANTIBODY FORMULATIONS
#443Human CGRP receptor binding proteins
#444Bovine fusion antibodies
#445Chimeric polypeptides comprising G protein-coupled receptors and VHH antibodies
#446Method and kit for detecting 1,25-dihydroxyvitamin D and related antibodies
#447Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants
#448Human anti TSHR antibodies
#449Human antibodies to the glucagon receptor and methods of use thereof
#450Modulators
#451Methods and compositions for increasing α-L-iduronidase activity in the CNS
#452Methods and compositions for determining resistance to androgen receptor therapy
#453ANTI-PROLACTIN RECEPTOR ANTIBODY FORMULATIONS
#454Antibody modulators of APLNR
#455Generating targeted sequence diversity in fusion proteins
#456Antibodies to non-functional oligomeric P2X7 receptors and methods of use thereof
#457Macromolecular compositions that cross the blood-brain barrier and methods of use thereof
#458Anti-ETBR antibodies and immunoconjugates
#459Anti-ETBR antibodies and immunoconjugates
#460PRLR-SPECIFIC ANTIBODY AND USES THEREOF
#461METHODS AND COMPOSITIONS FOR TREATING CANCER
#462ANTI-PROLACTIN RECEPTOR ANTIBODY FORMULATIONS
#463Fed batch method of making anti-TNF-alpha antibodies
#464Methods and compositions for increasing arylsulfatase A activity in the CNS
#465Anti-PRLR antibodies and methods for killing PRLR-expressing cells
#466Anti-PRLR antibodies and methods for killing PRLR-expressing cells
#467Therapeutic agent
#468ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
#469METHODS AND COMPOSITIONS FOR INCREASING ENZYME ACTIVITY IN THE CNS
#470Human PAC1 antibodies
#471Methods and compositions for increasing iduronate 2-sulfatase activity in the CNS
#472Pharmaceutical compositions comprising an antibody which binds the human anti-mullerian hormone receptor type II
#473Human growth hormone receptor antagonist antibodies and methods of use thereof
#474Targeted human-interferon fusion proteins
#475COMPOSITIONS AND METHODS FOR REGULATING CANCER-RELATED SIGNALING PATHWAYS
#476THERAPEUTIC COMBINATIONS AND METHODS OF TREATING MELANOMA
#477ANTAGONISTS FOR ABDOMINAL VASOPRESSIN V2 RECEPTOR AND USES THEREOF
#478Anti-glucagon receptor antibodies and pharmaceutical compositions thereof
#479Use of FSH receptor ligands for diagnosis and therapy of cancer
#480Method of treating endometriosis
#481Diagnostic and Treatment of an Androgen-Independent Prostate Cancer
#482TANDEM FC BISPECIFIC ANTIBODIES
#483Methods and compositions for increasing arylsulfatase A activity in the CNS
#484Macromolecular compositions that cross the blood-brain barrier and methods of use thereof
#485Inhibitors of metastasis, methods of generating such inhibitors and their therapeutic applications
#486BINDING COMPOUNDS TO HUMAN Beta 1-ADRENORECEPTOR (Beta 1-AR) AND THEIR USE IN MEASUREMENT OF AUTO-ANTI- Beta 1-AR ANTIBODIES
#487Anti-prolactin receptor antibody formulations
#488Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
#489Transcription unit and use thereof in expression vectors
#490Materials and methods for modulating activity of bone marrow derived cells
#491Prolactin receptor binding proteins and uses thereof
#492Bovine fusion antibodies
#493Anti-human EPO receptor antibodies and methods of use
#494Roles for Dual Endothelin-1/Angiotensin II Receptor (Dear) in hypertension and angiogenesis
#495Anti-GLP-1R antibodies and their uses
#496Neutralizing prolactin receptor antibody Mat3 and its therapeutic use
#497Fed-batch methods for producing adalimumab
#498Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal antibody variable regions
#499Bispecific monoclonal antibody therapeutics against West Nile virus with improved CNS penetration
#500Antibody production method
#501Method of increasing the effect of an activated-potentiated form of an antibody
#502Crystal structure
#503Anti-prolactin receptor antibody formulations
#504Humanized forms of monoclonal antibodies to human GnRH receptor
#505Nucleic acids encoding human glucagon receptor antibodies
#506Antibodies that bind to adrenomedullin and to adrenomedullin receptors and the uses thereof as drugs
#507METHODS OF TREATING CONDITIONS WITH ANTIBODIES THAT BIND COLONY STIMULATING FACTOR 1 RECEPTOR (CSF1R)
#508DEGRADED AGONIST ANTIBODY
#509Methods and compositions for increasing arylsulfatase A activity in the CNS
#510Neutralizing prolactin receptor antibodies and their therapeutic use
#511In vitro method for diagnosing or predicting hypertension and/or early-stage cardiovascular end-organ damage by determining the concentration of soluble prorenin receptor
#512Companion animal treatments
#513Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
#514Chimeric rabbit/human ROR1 antibodies
#515Anti-C-met antibody and methods of use thereof
#516Antibody against human prostaglandin Ereceptor EP4
#517Human monoclonal antibodies to the thyrotropin receptor which act as antagonists
#518Antibodies which bind type I cannabinoid receptor/angiotensis II receptor heteromers
#519Monoclonal antibodies and fragment thereof directed against the human anti-mullerian hormone type II receptor (AMHR-II)
#520Antibodies against glucagon receptor and their use
#521Methods and compositions for increasing arylsulfatase A activity in the CNS
#522Mutated humanized 12G4 antibodies and the fragments thereof against the human anti-Mullerian hormone receptor type II
#523Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
#524Neutralizing prolactin receptor antibodies and their therapeutic use
#525Anti-ferroportin 1 monoclonal antibodies and uses thereof
#526Method for immunizing animal, composition for immunization, method for producing antibody, method for producing hybridoma, and method for producing monoclonal antibody
#527Epitope regions of a thyrotrophin (TSH) receptor, uses thereof and antibodies thereto
#528Human CGRP Receptor Binding Proteins
#529Pharmaceutical compositions comprising activated-potentiated antibodies to human insulin receptor and endothelial nitric oxide (NO) synthase
#530Binding partners for the thyrotropin receptor and uses thereof
#531Monoclonal antibodies and binding fragments thereof directed to the melanocortin-4 receptor and their use in the treatment of cachexia and related conditions and diseases
#532NEUTRALIZING PROLACTIN RECEPTOR ANTIBODIES AND THEIR THERAPEUTIC USE
#533DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
#534Estrogen receptors and methods of use
#535Antigen binding sites to non-functional oligomeric P2X7 receptors and methods of use thereof
#536Estrogen receptors and methods of use
#537Estrogen receptors and methods of use
#538Method for detecting erythropoietin (EPO) receptor using anti-human EPO receptor antibodies
#539NEUTRALIZING PROLACTIN RECEPTOR ANTIBODIES AND THEIR THERAPEUTIC USE
#540NEUTRALIZING PROLACTIN RECEPTOR ANTIBODIES AND THEIR THERAPEUTIC USE
#541Medicament and a method for regulation of the vascular tone
#542Binding partners for the thyrotropin receptor and uses thereof
#543Bispecific anti-IGF-1R and anti-ErbB3 antibodies
#544Compositions and methods for blood-brain barrier delivery of IgG-decoy receptor fusion proteins
#545Monoclonal antibodies against gonadotropin-releasing hormone receptor
#546Monoclonal thyroid stimulating or blocking antibodies, peptide sequences corresponding to their variable regions, and their uses in diagnostic, preventive and therapeutic medicine
#547Combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system
#548ANTI-GPCR ANTIBODY AND THE METHOD OF PRODUCING THE SAME
#549Human antibodies to the human glucagon receptor and methods of use thereof
#550Antibodies for guanylyl cyclase receptors
#551Anti-ferroportin 1 monoclonal antibodies and uses thereof
#552CRYSTAL STRUCTURE
#553Methods of producing anti-TNF-alpha antibodies in mammalian cell culture
#554Combinatorial antibody libraries and uses thereof
#555Estrogen receptors and methods of use
#556Diagnosis and Treatment of Cancer Using Anti-LGR7 Antibody
#557Anti-DLL4 antibodies and uses thereof
#558Antibodies and methods for treating estrogen receptor-associated diseases
#559Human anti TSHR antibodies
#560Therapeutic uses of monoclonal antibodies to the angiotensin-II type 1 receptor
#561Methods for decreasing leptin levels or activity for treating inflammation
#562Compositions and methods relating to glucagon receptor antibodies
#563GLUCAGON RECEPTOR ANTAGONISTS
#564Therapeutic agent
#565GPCR crystalization method using an antibody
#566SHRNA-MEDIATED INHIBITION OF EXPRESSION OF ALPHA-1,6-FUCOSYLTRANSFERASE
#567PRLR-specific antibody and uses thereof
#568ROLES FOR DUAL ENDOTHELIN-1/ANGIOTENSIN II RECEPTOR (DEAR) IN HYPERTENSION AND ANGIOGENESIS
#569ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
#570ANTI-FERROPORTIN 1 MONOCLONAL ANTIBODIES AND USES THEREOF
#571Monoclonal antibodies against gonadotropin-releasing hormone receptor
#572Methods and compositions for increasing iduronate 2-sulfatase activity in the CNS
#573Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants
#574Anti-GLP-1R antibodies and their uses
#575Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal antibody variable regions
#576Modulators
#577Neutralizing human anti-IGFR antibody
#578Diagnosis and treatment of diseased and damaged tissue
#579Identification and characterization of a specific CCK-C receptor antibody for human pancreatic cancer and its use for early detection and staging of pancreatic cancer
#580Monoclonal antibodies and binding fragments thereof directed to the melanocortin-4 receptor and their use in the treatment of cachexia and related conditions and diseases
#581METHODS FOR MEASURING THE INSULIN RECEPTOR ALPHA SUBUNIT
#582Inverse agonist monoclonal antibody that suppresses thyrotropin receptor constitutive activity
#583Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
#584Use of FSH receptor ligands for diagnosis and therapy of cancer
#585Method for treating pruritus comprising administering an NR10 antagonist
#586Methods for diagnosing CNS disorders with fusion antibodies that cross the blood-brain barrier in both directions
#587Antibody that binds to ER-α36
#588Anti-mullerian inhibiting substance type II receptor (MISIIR) immunoconjugates to detect and treat cancer
#589Serum Prolactin Binding Protein in Epithelial Carcinoma
#590Agonist antibodies against TSHR
#591Fusion proteins for delivery of erythropoietin to the CNS
#592Medicament and a method for regulation of the vascular tone
#593Crystal structure of thyroid stimulating hormone receptor
#594Treatments Which Alleviate Functional Glycosylated Leptin Transport Factor for Controlling Weight and Obesity
#595Human CGRP receptor binding proteins
#596ORAL DELIVERY OF POLYPEPTIDES
#597Anti-FC-receptor single domain antibodies (nanobodies-tm) and therapeutic use
#598Monoclonal antibodies and fragment thereof directed against the human Anti-Müllerian Hormone type II receptor (AMHR-II)
#599Light targeting molecules and uses thereof
#600Antibodies against RAMP3